REMS Audits Fall To NDA Sponsors; First Reviews Entail Rejection/Re-Review

FDA will be relying on NDA sponsors to conduct audits of pharmacies and providers rather than policing compliance with REMS (risk evaluation and mitigation strategies) on its own, Sidley Austin partner Coleen Klasmeier suggested during a Nov. 13 webinar